Cancer signal both feeds tumors and boosts immunity

Cells communicate through signaling molecules. One such pathway is called JAK-STAT: a cascade in which an outside signal activates a response inside the cell. In breast cancer, JAK-STAT has long been known to promote tumor growth, making it an attractive target for treatment.

But the research, published in eLife, reveals another face of the same pathway. JAK-STAT activation simultaneously boosts the immune system’s response to the tumor. That could make immunotherapy, treatments that use the body’s own immune system to fight cancer, more effective.

Two faces of the same signal

This dual effect has significant clinical implications. If doctors block JAK-STAT to suppress tumor growth, they may simultaneously dampen the immune response that therapy depends on. Conversely, leaving JAK-STAT active can feed the tumor while also amplifying immune activity.

The researchers describe this as two faces of the same signal. Which face dominates likely depends on context: the type of tumor, disease stage, and which other signals are active at the same time. That makes fine-tuning JAK-STAT-based therapies more complicated than previously thought.

Implications for cancer immunotherapy

For cancer treatment, this is a relevant finding. Immunotherapy does not work equally well for all patients. If JAK-STAT partly determines how well the immune system responds to a tumor, a better understanding of this pathway could help predict who benefits most from which treatment.

This is laboratory research. Whether the findings hold in patients, and how the balance between tumor promotion and immune activation plays out in practice, are questions for clinical studies. Still, the study adds meaningful nuance to the understanding of a pathway already widely investigated as a therapeutic target across multiple cancer types.

Read the original article